Results 221 to 230 of about 58,361 (283)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source

Kidney Disease and Mineralocorticoid Receptor

Nihon Naika Gakkai Zasshi, 2009
openaire   +3 more sources

Prostaglandin D₂ Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone-Mineralocorticoid Receptor Pathway in the Heart. [PDF]

Cells
Garg A, Juchem M, Biss S, Borisch CN, Leonardy J, Bär C, Gupta SK, Thum T.   +7 more
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source

From Receptor to Repair: The Mechanistic Basis of Mineralocorticoid Receptor Antagonism in Acute Kidney Injury and CKD. [PDF]

Kidney360
Liu R, Lu Y, Juncos LA.
europepmc   +1 more source

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

Components of Mineralocorticoid Receptor System in Human DRG Neurons Co-Expressing Pain-Signaling Molecules: Implications for Nociception. [PDF]

Cells
Mousa SA, Hong X, Metwally EY, Tafelski S, Wandrey JD, Piontek J, Treskatsch S, Schäfer M, Shaqura M.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists

Current Hypertension Reports, 2007
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan, MacDonald, Thomas M.   +1 more
openaire   +3 more sources